GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

University Hospital, Gentofte, Copenhagen

Status: Completed

Conditions: Type2 Diabetes

Treatments: Other: GIP receptor antagonist; Drug: DPP-4 inhibitor; Other: Placebo tablet; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03845179

H-18040916

Details and patient eligibility

About

This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.

Full description

A randomized, placebo controlled study. Using a GIP receptor antagonist, we will investigate the glucose lowering effect of GIP during treatment with DPP-4 inhibitors.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• type 2 diabetes, treatment: lifestyle changes or metformin
• HbA1c < 75 mmol/mol

Exclusion criteria

• diagnosed liver disease
• eGFR < 60 ml/min/1,73m2
• NYHA III or IV
• anemia.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

12 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)

Treatment:

Other: Placebo

Other: Placebo tablet

Other: GIP receptor antagonist

DPP-4 inhibitor

Active Comparator group

Description:

DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)

Treatment:

Other: Placebo

Drug: DPP-4 inhibitor

Other: GIP receptor antagonist